Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of SYH9056 in patients with mild-to-moderate essential hypertension inadequately controlled after 4 weeks of monotherapy
CTR20244681Phase 3Completed
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of valsartan, Levamlodipine in essential hypertension, sponsored by CSPC ZhongQi Pharmaceutical Technology. Started Dec 2024; status: completed.
02
Drugs
valsartanLevamlodipine
03
Conditions
essential hypertension
Beyond the preview
Go deeper on CTR20244681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244681.